MIM
ENZ

MetLife Investment Management’s Enzo Biochem, Inc. ENZ Stock Holding History

MetLife Investment Management’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-21,985
Closed -$120K – 2231
2018
Q1 		$120K Hold
21,985
– – ﹤0.01% 2130
2017
Q4 		$179K Buy
+21,985
New +$210K ﹤0.01% 1990

Other funds holding ENZ

EGA
Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MetLife Investment Management's ENZ Position: Q2 2018 in Review

MetLife Investment Management sold out of Enzo Biochem, Inc. (ENZ) in Q2 2018, closing a stake of 21,985 shares — an estimated $120K sold.

MetLife Investment Management first reported a position in ENZ in Q4 2017 and held it in 2 quarters. The position peaked at $179K in Q4 2017. 97 funds tracked by Wall St. Rank hold ENZ as of Q2 2018.

  • MetLife Investment Management reported no remaining Enzo Biochem, Inc. position as of Q2 2018 after selling out during the quarter.
  • MetLife Investment Management sold 21,985 Enzo Biochem, Inc. shares in Q2 2018, an estimated $120K.
  • MetLife Investment Management first reported a position in Enzo Biochem, Inc. in Q4 2017 and held it in 2 quarters.
  • MetLife Investment Management's Enzo Biochem, Inc. position peaked at $179K in Q4 2017.
  • 97 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2018.

Based on MetLife Investment Management's 13F filing for Q2 2018, filed 15 Aug 2018.